Genoa Ventures

Genoa Ventures aims to improve the performance and stability of its portfolio companies. Its team has experience in investing, operating, research, discovery, and launching and scaling businesses across the biology and technology sectors.

Investing in Early-Stage Companies Innovating at the Intersection of Biology and Technology.

HydRegen secures £6 million in Series A funding to advance its bio-based hydrogenation platform. The round is led by Genoa Ventures, with support from the Clean Growth Fund. The Oxford- and San Francisco-based biotech startup aims to commercialize its technology for sustainable hydrogen production.

Oct 2026Startupmag.co.ukNews article

Epitel raises **$26 million in Series B funding** to scale its **FDA-cleared, fully wireless EEG system**, enabling AI-powered remote brain monitoring. The company’s technology eliminates traditional wired constraints, broadening access to continuous neurological monitoring outside clinical settings. This expansion targets commercial adoption across healthcare providers and research applications.

Jul 2026Utah BusinessNews article

Epitel secures **$26 million in Series B funding** to expand its remote electroencephalography (EEG) infrastructure. The capital will support commercial infrastructure growth, provider adoption, and market access in ambulatory care settings. The company aims to scale its remote EEG solutions for broader healthcare applications.

Jul 2026Medical Product OutsourcingNews article

Genoa Ventures promotes Landon Merrill to partner, expanding its leadership in venture capital focused on science-driven startups. The firm specializes in backing companies with transformative scientific potential. Merrill’s new role underscores Genoa’s commitment to deep expertise in early-stage investments across life sciences and technology sectors.

Oct 2024Venture Capital Access OnlineNews article